Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125403291 | 12540329 | 1 | I | 20160629 | 20160708 | 20160708 | EXP | US-VIIV HEALTHCARE LIMITED-US2016GSK097190 | VIIV | PUERTOLAS MV, BOLTON MT, STEELE RW. LATE ELISA TESTING IN INFANTS BORN TO HIV-POSITIVE MOTHERS. CLINICAL PEDIATRICS. 2016;55 (7):673-676 | 0.00 | N | M | Y | 0.00000 | 20160708 | MD | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125403291 | 12540329 | 1 | PS | ZIDOVUDINE. | ZIDOVUDINE | 1 | Transplacental | 2 MG/KG, UNK | U | 19655 | 2 | MG/KG |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125403291 | 12540329 | 1 | Antiviral prophylaxis |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125403291 | 12540329 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125403291 | 12540329 | Decreased appetite | |
125403291 | 12540329 | Diarrhoea | |
125403291 | 12540329 | Foetal exposure during pregnancy | |
125403291 | 12540329 | HIV infection | |
125403291 | 12540329 | Hepatosplenomegaly | |
125403291 | 12540329 | Lymphadenopathy | |
125403291 | 12540329 | Oral candidiasis | |
125403291 | 12540329 | Rhinorrhoea | |
125403291 | 12540329 | Viral load increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |